Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified-Reference-Cited by-同舟云学术

Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified

Published:2022-08-26 Issue:1 Volume:31 Page:210-224
ISSN:0803-7051
Container-title:Blood Pressure
language:en
Short-container-title:Blood Pressure

Author:

Esler Murray¹^ORCID,Kjeldsen Sverre E.²^ORCID,Pathak Atul³^ORCID,Grassi Guido⁴^ORCID,Kreutz Reinhold⁵^ORCID,Mancia Giuseppe⁴^ORCID

Affiliation:

1. Baker Heart and Diabetes Institute, Human Neurotransmitters Laboratory and Monash University, Melbourne, Australia

2. Department of Cardiology, Ullevaal Hospital, University of Oslo, Oslo, Norway

3. Department of Cardiology, and UMR UT3 CNRS 5288 Hypertension and heart failure: molecular and clinical investigations, INI-CRCT F-CRIN, GREAT Networks, Centre Hospitalier Princesse Grace, Monte Carlo, Monaco;

4. University of Milano-Bicocca, Milan, Italy

5. Charité – Medical University of Berlin, Institute of Clinical Pharmacology and Toxicology, Berlin, Germany

Funder

N.a.

Publisher

Informa UK Limited

Subject

Cardiology and Cardiovascular Medicine,General Medicine,Internal Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/08037051.2022.2110858

Reference75 articles.

1. 2018 ESC/ESH Guidelines for the management of arterial hypertension

2. 2020 International Society of Hypertension Global Hypertension Practice Guidelines

3. Diagnosis and management of hypertension in adults: NICE guideline update 2019

4. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physicians’ attitudes toward beta‐blockers for the treatment of hypertension in Italy, Poland, and Turkey;The Journal of Clinical Hypertension;2024-05-15

2. Beta-blocker bashing and downgrading in hypertension management: a fashionable trend representing a matter of concern;Journal of Hypertension;2024-05-01

3. Recommandations ESH 2023 : qu’en retenir pour la pratique ?;Archives des Maladies du Coeur et des Vaisseaux - Pratique;2024-05

4. The role of β-blockers in medical treatment;Current Medical Research and Opinion;2024-04

5. A foreword from the supplement sponsor;Current Medical Research and Opinion;2024-04